Results 31 to 40 of about 32,734 (287)

Homologous and Heterologous Covid-19 Booster Vaccinations

New England Journal of Medicine, 2022
Although the three vaccines against coronavirus disease 2019 (Covid-19) that have received emergency use authorization in the United States are highly effective, breakthrough infections are occurring. Data are needed on the serial use of homologous boosters (same as the primary vaccine) and heterologous boosters (different from the primary vaccine) in ...
Robert L. Atmar, Kirsten E. Lyke, Meagan E. Deming, Lisa A. Jackson, Angela R. Branche, Hana M. El Sahly, Christina A. Rostad, Judith M. Martin, Christine Johnston, Richard E. Rupp, Mark J. Mulligan, Rebecca C. Brady, Robert W. Frenck, Martín Bäcker, Angelica C. Kottkamp, Tara M. Babu, Kumaravel Rajakumar, Srilatha Edupuganti, David Dobrzynski, Rhea N. Coler, Christine M. Posavad, Janet I. Archer, Sonja Crandon, Seema U. Nayak, Daniel Szydlo, Jillian A. Zemanek, Clara P. Dominguez Islas, Elizabeth R. Brown, Mehul S. Suthar, M. Juliana McElrath, Adrian B. McDermott, Sarah E. O’Connell, David C. Montefiori, Amanda Eaton, Kathleen M. Neuzil, David S. Stephens, Paul C. Roberts, John H. Beigel   +37 more
openaire   +2 more sources

Self-reported adverse events after 2 doses of COVID-19 vaccine in Korea [PDF]

Epidemiology and Health, 2022
OBJECTIVES In Korea, a national coronavirus disease 2019 (COVID-19) vaccination program was implemented, including 4 vaccines against COVID-19. A text messaging-based survey, in addition to a passive adverse event reporting system, was launched to ...
Yunhyung Kwon, Insob Hwang, Mijeong Ko, Hyungjun Kim, Seontae Kim, Soon-Young Seo, Enhi Cho, Yeon-Kyeng Lee   +7 more
doaj   +1 more source

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study

Human Vaccines & Immunotherapeutics, 2023
The global supply of COVID-19 vaccines has been limited, and concerns have arisen about vaccine supply chain disruptions in developing countries. Heterologous prime-boost vaccination, which involves using different vaccines for the first and second doses,
Kriangkrai Tawinprai, Pawornrath Jungsomsri, Onnicha Pinijnai, Fahsiri Tavonvunchai, Anchisa Lievjaroen, Paphada Suwannaroj, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Gaidganok Sornsamdang, Teerapat Ungtrakul   +9 more
doaj   +1 more source

BCG vaccination induces different cytokine profiles following infant BCG vaccination in the UK and Malawi [PDF]

, 2011
BACKGROUND: BCG vaccination of infants is thought to provide good protection in all settings. This study investigated whether Malawian infants made weaker responses across a cytokine panel after BCG vaccination, compared with UK infants.METHODS: Diluted ...
Hazel M. Dockrell, Newport, Melanie J, Mvula, Hazzie, Weir, Rosemary E., Rose Blitz, Fine, P.E., Steven G. Smith, Nuala McGrath (230042), Crampin, Amelia C, Keith Branson (239422), Hazel M Dockrell (10414616), Sian Floyd, Fine, Paul E, Crampin, Amelia C., Weir, R.E., McGrath, N., Floyd, Sian, Rose Blitz (356877), Newport, M.J., Anne Ben-Smith (244056), Melanie Newport (4461202), Lalor, Maeve K., Hazzie Mvula, Lalor, M.K., Maeve K Lalor (16181825), Sian Floyd (239400), Weir, Rosemary E, Lalor, Maeve K, Gorak-Stolinska, P., Fine, Paul E., Nuala McGrath, Crampin, A.C., Ben-Smith, A., Steven G Smith (16181831), Maeve K. Lalor, Hazzie Mvula (271278), Smith, S.G., Mvula, H., Smith, Steven G., Smith, Steven G, Patricia Gorak-Stolinska (356875), Floyd, S., Blitz, R., McGrath, Nuala, Amelia C. Crampin, Gorak-Stolinska, Patricia, Rosemary E. Weir, Branson, K., Amelia C Crampin (10281422), Ben-Smith, Anne, Dockrell, Hazel M., Paul E. Fine, Paul E Fine (16181834), Blitz, Rose, Dockrell, H.M., Rosemary E Weir (16181828), Keith Branson, Anne Ben-Smith, Dockrell, Hazel M, Newport, Melanie J., Branson, Keith, Patricia Gorak-Stolinska, Melanie J. Newport   +62 more
core   +2 more sources

Vaccination and heterologous immunity: educating the immune system [PDF]

Transactions of The Royal Society of Tropical Medicine and Hygiene, 2015
This review discusses three inter-related topics: (1) the immaturity of the neonatal and infant immune response; (2) heterologous immunity, where prior infection history with unrelated pathogens alters disease outcome resulting in either enhanced protective immunity or increased immunopathology to new infections, and (3) epidemiological human vaccine ...
Gil, Anna, Kenney, Laurie L., Mishra, Rabinarayan, Watkin, Levi B., Aslan, Nuray, Selin, Liisa K.   +5 more
openaire   +3 more sources

Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination. [PDF]

, 2007
Mycobacterium bovis BCG is widely used as a vaccine against tuberculosis (TB), despite its variable protective efficacy. Relatively little is known about the immune response profiles following BCG vaccination in relation to protection against TB. Here we
Klein, Michèl R, Friggen, Annemieke H, Geluk, Annemieke, Lin, May Young, Verduyn, Marleen JC, Voskuil, Martin I, Huygen, Kris, Franken, Kees LMC, Smith, Steven G, van Meijgaarden, Krista E, Dockrell, Hazel M, Stewart, Amanda L, Ottenhoff, Tom HM   +12 more
core   +2 more sources

Heterologous prime–boost strategies for COVID-19 vaccines [PDF]

Journal of Travel Medicine, 2021
AbstractBackground/ObjectiveHeterologous prime–boost doses of COVID-19 vaccines (‘mix-and-match’ approach) are being studied to test for the effectiveness of Oxford (AZD1222), Pfizer (BNT162b2), Moderna (mRNA-1273) and Novavax (NVX-CoV2373) vaccines for COVID in ‘Com-Cov2 trial’ in UK, and that of Oxford and Pfizer vaccines in ‘CombivacS trial’ in ...
Binaya Sapkota, Bhuvan Saud, Ranish Shrestha, Dhurgham Al-Fahad, Ranjit Sah, Sunil Shrestha, Alfonso J Rodriguez-Morales   +6 more
openaire   +2 more sources

Heterologous vaccine regimen: Stakeholder acceptance and implementation considerations

Vaccine, 2021
Heterologous vaccine regimens deliver antigens through different vaccine components or vector types at sequential time points. Clinical development shows promising results and several candidates may be progressing to licensure in the coming years. This study aimed at exploring future acceptance and uptake of such regimens (also called heterologous ...
Helena Greter, Sabrina Ivol, Valérie Oriol Mathieu, Séverine Erismann, Helen Prytherch, Peter Steinmann   +5 more
openaire   +3 more sources

Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial

Frontiers in Immunology, 2023
Background/PurposeOptimizing vaccine efficacy is of particular concern in patients undergoing hematopoietic stem cell transplantation (HSCT), which mainly have an inadequate immune response to primary SARS-CoV-2 vaccination.
Leyla Sharifi Aliabadi, Manoochehr Karami, Manoochehr Karami, Maryam Barkhordar, Seyed Saeed Hashemi Nazari, Amir Kavousi, Mohammad Ahmadvand, Mohammad Vaezi, Mohammad Vaezi   +8 more
doaj   +1 more source

Pathogenic epitopes, heterologous immunity and vaccine design [PDF]

Nature Reviews Microbiology, 2007
Substantial research has been directed towards the development of a new generation of vaccines that are based on the inclusion of immunogenic epitopes in recombinant vectors. Here we examine the evidence that under certain conditions immunogenic epitopes can do more harm than good and might therefore be considered pathogenic.
Welsh, Raymond M., Fujinami, Robert S.
openaire   +2 more sources